Completed PHASE2 INTERVENTIONAL 2-arm NCT00974376

Gabapentin Treatment of Cannabis Dependence

Sponsor: National Institute on Drug Abuse (NIDA)

Conditions Cannabis Dependence Cannabis Withdrawal Cognitive Deficits

Interventions Manual-guided behavioral counseling Placebo gabapentin 1200mg/day

Updated 9 times since 2017 Last updated: May 8, 2017 Started: Nov 4, 2009 Primary completion: May 19, 2016 Completion: May 19, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Cannabis Dependence and Cannabis Withdrawal and is currently completed. National Institute on Drug Abuse (NIDA) leads this study, which shows 9 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jul 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Jul 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute on Drug Abuse (NIDA)
The Scripps Research Institute

Data source: The Scripps Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• La Jolla, United States